Applied Dna Scie SEC Filings

Applied DNA Sciences disclosed an insider equity award. On 10/17/2025, Chief Financial Officer Beth Jantzen acquired 18,691 shares reported as common stock at $0 per share, tied to a restricted stock unit grant. The filing states 100% of the RSUs vest 90 days from the grant date. Following this grant, her beneficial ownership stood at 18,694 shares, held directly.

Applied DNA Sciences reported an insider transaction on a Form 4. A director received 22,511 shares of common stock on 10/17/2025, listed with Transaction Code "A" at a price of $0.

Following this award, the reporting person beneficially owned 22,512 shares held directly. The filing notes the grant is in the form of restricted stock units that vest 100% after 90 days from the date of grant.

Applied DNA Sciences filed a Form 4 showing a director acquired 22,511 shares of common stock at $0 on 10/17/2025. Following the transaction, the director beneficially owns 22,512 shares, held directly. The filing notes that 100% of the related restricted stock units vest 90 days from the date of grant.

Applied DNA Sciences reported an insider equity change on a Form 4. A director acquired 18,691 shares of common stock on 10/17/2025 with a reported price of $0 (transaction code A). Following the transaction, the reporting person beneficially owns 18,694 shares, held directly.

The filing notes that 100% of the restricted stock units vest upon 90 days from the date of grant, indicating the award structure tied to service over a short vesting period.

Applied DNA Sciences reported an insider equity change. The Chief Executive Officer filed a Form 4 showing acquisition of 18,691 shares of common stock on 10/17/2025 at a price of $0, coded “A.” Following the transaction, the officer beneficially owned 18,695 shares, held directly.

The filing notes that 100% of the related restricted stock units vest 90 days from the date of grant.

Applied DNA Sciences announced a corporate restructuring to refocus resources on a BNB-focused treasury strategy. The company will cut its workforce by 16 employees, about 60% of staff, and expects to incur approximately $1.4M of pre-tax charges for severance, benefits, and related costs. Management expects the reduction-in-force to be substantially completed by end of October 2025 and for the charges to be recorded in the first quarter of fiscal 2026. The company estimates the plan will generate annualized cost savings of about $2.9M, but cautions the estimates rely on assumptions and actual amounts may differ materially, including potential additional costs.

Applied DNA Sciences, Inc. (APDN) filed a Form 8-K disclosing a set of exhibits dated September 29, 2025. The filing lists forms of financing and related documents, including cash and cryptocurrency securities purchase agreements, multiple warrant forms (prefunded, common, cryptocurrency, advisory, and placement agent warrants), registration rights agreements, and a Strategic Digital Asset Services Agreement plus a related Strategic Advisor Agreement with Cypress entities. The exhibit list also includes employment and separation agreements, a press release, a supplemental business description, and supplemental risk factors. These exhibits indicate contemporaneous arrangements covering securities issuance mechanics, digital-asset-related services/advisory support, and personnel agreements that could affect corporate structure and capitalization.

Applied DNA Sciences, Inc. entered a three-year consulting and sponsorship arrangement through September 23, 2028, under which a named Consultant will provide advisory and marketing services and deliver premium sponsorship benefits at all SALT conferences globally for 36 months.

The Company will pay the Consultant a total upfront/contracted fee structure including $1,000,000 and additional amounts of $250,000 paid quarterly from December 2025 until September 2027. Immediately following the closing of the referenced Offering, the Consultant will receive warrants exercisable for a number of common shares equal to 1% of the fully diluted outstanding equity of the Company as of immediately after that closing. The Consultant Warrants have an exercise price equal to 115% of the per-share purchase price under the Securities Purchase Agreement, are exercisable for cash for five years, and may be exercised on a cashless basis beginning six months after issuance if resale registration is not available.

The filing is signed by Clay Shorrock, Chief Executive Officer.

Applied DNA Sciences, Inc. has a Schedule 13G reporting that three related reporting persons—Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC—may be deemed to beneficially own 143,336 shares of common stock, representing 9.99% of the common stock on a diluted basis. The filing explains those shares are issuable upon exercise of a warrant held by Intracoastal ("Intracoastal Warrant 1") and notes blocker provisions that limit exercise to avoid exceeding 9.99% (and a second warrant with a 4.99% blocker). The report lists shared voting and dispositive power over the 143,336 shares and provides addresses and citizenship of the reporting persons. The filing includes signed certifications and a joint filing agreement.